908 Devices downgraded by Leerink Partners with a new price target
$MASS
Industrial Machinery/Components
Industrials
Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 2/7/2023 | $14.00 | Overweight | Stephens |
| 3/8/2022 | $40.00 → $30.00 | Outperform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen |
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that the Metropolitan Washington Council of Governments (COG) has purchased eight XplorIR devices, one for each of the seven counties and District of Columbia, which comprise the COG. The devices were shipped in Q1 2025, with training taking place in Q2 2025. The handheld XplorIR device accurately detects, identifies, and quantifies 5,000 unknown gas and vapor chemical threats in seconds. The device has simple controls, an intuitive display and is built for harsh environments, making it easy for first responders to use in emergency situations. "The XplorIR is a crucial addition t
The handheld mass spectrometers are now in active use for trace detection and identification of drugs and explosives for customs and border patrol applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that the Romanian Customs Authority has fully deployed 27 MX908 devices across its border operations. The units were delivered earlier this year and are now actively supporting frontline officers with real-time identification of trace chemicals, enhancing the country's ability to monitor cross-border movement and investigate suspicious substances with speed and precision. "We have already experienced the benefits of the MX
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming William Blair 45th Annual Growth Stock Conference. 908 Devices' management is scheduled to present on Wednesday, June 4 at 4 p.m. Central Time / 5 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.908devices.com. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company's d
SD - 908 Devices Inc. (0001555279) (Filer)
SCHEDULE 13G/A - 908 Devices Inc. (0001555279) (Subject)
10-Q - 908 Devices Inc. (0001555279) (Filer)
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini
908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as
Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in
At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re
Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00
SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously